Related Experiment Video
Updated: Jul 2, 2026

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
Published on: July 16, 2016
Activation of a Yap1-mesenchymal-like program in β-cells during diabetes
Wendy M McKimpson1, Nehan Hoque2, Matthew Barter3
1Department of Medicine, Division of Endocrinology, Columbia University, New York, NY, USA; Naomi Berrie Diabetes Center, Columbia University, New York, NY, USA; Department of Medicine, Division of Digestive Diseases, Emory University, Atlanta, GA, USA.
Abstract:
A critical driver of type 2 diabetes is the failure of insulin-secreting β cells due to dysfunction and loss of cell number or identity. The signaling pathways that trigger these events remain unclear. Here, we identify an epithelial-to-mesenchymal (EMT)-like program that is activated in β cells to promote their loss with type 2 diabetes. This program is initiated in human and mouse β cells by the EMT transcription factor Yap1. While this protein is normally not present in β cells, Yap1 becomes upregulated in response to oxidative stress and impaired mitochondrial function. Chemical inhibition of Yap1 in islets reverses EMT-like activation while its overexpression in cells triggered the appearance of mesenchymal-like vimentin+ cells. Functionally, blocking Yap1 in isolated islets and in mice improves insulin secretion and alleviates diabetes. Taken together, we have identified a novel pathway of β-cell failure during type 2 diabetes, revealing a potential target for future diabetes treatment.
Insights
Type 2 diabetes involves beta-cell failure. Researchers found that the Yap1 protein triggers an EMT-like program in beta cells, leading to their loss and driving diabetes progression.
Area of Science:
- Cell Biology
- Endocrinology
- Metabolic Diseases
Background:
- Type 2 diabetes is characterized by beta-cell dysfunction and loss.
- The underlying signaling pathways driving beta-cell failure are not fully understood.
Purpose of the Study:
- To identify the signaling pathways responsible for beta-cell loss in type 2 diabetes.
- To investigate the role of the Yap1 transcription factor in beta-cell failure.
Main Methods:
- Investigated Yap1 expression in human and mouse beta cells under diabetic conditions.
- Utilized chemical inhibition and overexpression of Yap1 in isolated islets and mouse models.
- Assessed changes in epithelial-to-mesenchymal (EMT)-like markers (e.g., vimentin) and insulin secretion.
Main Results:
- Yap1 is upregulated in beta cells in response to oxidative stress and mitochondrial dysfunction.
- Yap1 activation initiates an EMT-like program in beta cells, leading to vimentin expression.
- Inhibition of Yap1 reversed EMT-like changes, improved insulin secretion, and alleviated diabetes in mice.
Conclusions:
- Yap1 acts as a critical initiator of beta-cell loss via an EMT-like program in type 2 diabetes.
- Targeting Yap1 represents a potential therapeutic strategy for treating type 2 diabetes.
Related Concept Videos
Cell Specific Gene Expression
Insulin Secretory Vesicles
Type I Diabetes II: Pathophysiology
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Type II Diabetes II: Pathophysiology
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...

